What Is End-of-Life Care Like for Metastatic Uveal Melanoma?
By CRYSTAL BAI •
The short answer: Uveal (ocular) melanoma is the most common primary eye cancer in adults, with a high rate of liver metastasis. Once metastatic, prognosis is poor with median survival of 6-12 months. End-of-life care focuses on managing liver-related symptoms, pain, fatigue, and the emotional burden of vision loss preceding metastatic diagnosis.
Understanding Metastatic Uveal Melanoma
Uveal melanoma (also called ocular melanoma or intraocular melanoma) arises from pigment cells in the uveal tract of the eye — choroid, ciliary body, or iris. Despite effective local treatment of the primary tumor, approximately 50% of patients develop metastatic disease, almost always to the liver.
Metastatic uveal melanoma has historically been extremely resistant to treatment, with median survival of 6-12 months from metastatic diagnosis. Tebentafusp (Kimmtrak), the first approved therapy, has shown modest survival benefit in HLA-A*02:01-positive patients. Liver-directed therapies (TACE, SIR-spheres) are used in selected patients.
Symptoms in Metastatic Uveal Melanoma
Because uveal melanoma predominantly metastasizes to the liver, the symptom pattern mirrors advanced hepatic disease:
- Hepatomegaly: Enlarged liver causing upper abdominal pressure, discomfort, and early satiety
- Liver failure signs: Jaundice, ascites, fatigue, confusion as hepatic function declines
- Pain: Right upper quadrant and abdominal pain from liver capsule distension
- Fatigue: Often profound from hepatic burden and treatment side effects
- Nausea: From liver involvement and ascites
- Pulmonary and bone metastases: Less common but can occur, adding respiratory and pain symptoms
Psychosocial Dimensions of Uveal Melanoma
Uveal melanoma presents unique psychosocial challenges:
- Vision loss: Treatment of the primary tumor (enucleation, radiation) may cause significant vision loss or complete blindness — patients are often adapting to disability during disease monitoring
- Waiting for metastasis: The years of surveillance after primary treatment, knowing recurrence risk is high, create chronic anxiety
- Shock of rapid progression: Patients who have been surveilled for years may be shocked when metastasis is finally detected and rapid deterioration follows
Palliative Care for Uveal Melanoma
Palliative care in metastatic uveal melanoma focuses on liver symptom management:
- Pain: Multimodal analgesia for hepatic capsule and visceral pain
- Ascites: Paracentesis or drainage catheter
- Fatigue management: Activity pacing, sleep hygiene, brief steroid courses
- Advance care planning: Given rapid progression potential, early advance directive completion is essential
Uveal Melanoma Community Resources
The Ocular Melanoma Foundation (ocularmelanoma.org) and Melanoma Research Foundation provide patient community and clinical trial information. The Liver Tumor Study Group at major cancer centers specializes in uveal melanoma liver management.
Frequently Asked Questions
What is the prognosis for metastatic uveal melanoma?
Metastatic uveal melanoma has a historically poor prognosis, with median overall survival of approximately 6-12 months. Tebentafusp (Kimmtrak), approved in 2022 for HLA-A*02:01-positive patients, was the first therapy to show a survival benefit, extending median survival modestly. Individual prognosis depends on liver tumor burden, performance status, and eligibility for liver-directed treatments.
Why does uveal melanoma spread to the liver?
Uveal melanoma has an unusually specific tropism (affinity) for the liver, related to the liver's blood supply receiving drainage from the portal circulation and specific surface markers on uveal melanoma cells that interact with liver tissue. Unlike cutaneous melanoma, uveal melanoma almost exclusively metastasizes to the liver.
Is liver transplant possible for uveal melanoma liver metastases?
Liver transplant for uveal melanoma metastases has been investigated in small series, with mixed results. It is experimental and not standard of care. Most patients are not surgical candidates at metastatic diagnosis due to bilateral or multifocal liver involvement. This should be discussed with a specialist at a high-volume uveal melanoma center.
How long do uveal melanoma surveillance periods last?
High-risk uveal melanoma patients typically undergo surveillance imaging (liver MRI or ultrasound, chest CT) every 6 months for at least 5-10 years after primary treatment, as recurrence can occur late. The prolonged surveillance period creates years of anxiety about potential recurrence — mental health support during this period is underutilized but valuable.
What clinical trials are available for uveal melanoma?
Clinical trials for uveal melanoma include immunotherapy combinations, liver-directed therapy studies, MEK inhibitor trials, and T-cell receptor therapy investigations. ClinicalTrials.gov is the authoritative source; the Ocular Melanoma Foundation also maintains trial listings. High-volume centers with uveal melanoma programs (Wills Eye, Bascom Palmer, MSKCC) are most likely to have active trials.
Renidy connects grieving families with compassionate death doulas and AI-powered funeral planning tools. Try our free AI funeral planner or find a death doula near you.